Relay Therapeutics, Inc.

NasdaqGM:RLAY Voorraadrapport

Marktkapitalisatie: US$915.5m

Relay Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Relay Therapeutics is Sanjiv Patel, benoemd in Mar2017, heeft een ambtstermijn van 7.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 19.77M, bestaande uit 3.4% salaris en 96.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.84% van de aandelen van het bedrijf, ter waarde $ 7.70M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 5.3 jaar.

Belangrijke informatie

Sanjiv Patel

Algemeen directeur

US$19.8m

Totale compensatie

Percentage CEO-salaris3.4%
Dienstverband CEO7.7yrs
Eigendom CEO0.8%
Management gemiddelde ambtstermijn6.6yrs
Gemiddelde ambtstermijn bestuur5.3yrs

Recente managementupdates

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Analyse CEO-vergoeding

Hoe is Sanjiv Patel's beloning veranderd ten opzichte van Relay Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$20mUS$674k

-US$342m

Sep 30 2023n/an/a

-US$326m

Jun 30 2023n/an/a

-US$344m

Mar 31 2023n/an/a

-US$323m

Dec 31 2022US$8mUS$642k

-US$291m

Sep 30 2022n/an/a

-US$290m

Jun 30 2022n/an/a

-US$267m

Mar 31 2022n/an/a

-US$384m

Dec 31 2021US$9mUS$603k

-US$364m

Sep 30 2021n/an/a

-US$261m

Jun 30 2021n/an/a

-US$414m

Mar 31 2021n/an/a

-US$247m

Dec 31 2020US$4mUS$585k

-US$230m

Sep 30 2020n/an/a

-US$289m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$86m

Dec 31 2019US$4mUS$585k

-US$75m

Compensatie versus markt: De totale vergoeding ($USD 19.77M ) Sanjiv } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.25M ).

Compensatie versus inkomsten: De vergoeding van Sanjiv is gestegen terwijl het bedrijf verliesgevend is.


CEO

Sanjiv Patel (50 yo)

7.7yrs

Tenure

US$19,770,838

Compensatie

Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Alexis Borisy
Co-Founder & Independent Chairman9.6yrsUS$581.14k0.14%
$ 1.3m
Sanjiv Patel
CEO, President & Director7.7yrsUS$19.77m0.84%
$ 7.7m
Mark Murcko
Co-Founder & Directorno dataUS$548.64k0.61%
$ 5.6m
Thomas Catinazzo
Chief Financial Officer6.6yrsUS$5.22m0.0092%
$ 84.4k
Brian Adams
Chief Legal Officer & Secretary6.7yrsUS$4.51m0.024%
$ 223.7k
Peter Rahmer
Chief Corporate Development Officerno dataUS$6.78m0.0091%
$ 83.0k
Donald Bergstrom
President of Research & Development6.6yrsUS$8.57m0.040%
$ 362.8k
Dorothee Kern
Founderno datageen gegevensgeen gegevens
David Shaw
Founderno datageen gegevensgeen gegevens
Matthew Jacobson
Founderno datageen gegevensgeen gegevens
Jim Watters
Chief Scientific Officerless than a yeargeen gegevensgeen gegevens
Jeanne Gray
Chief People Officerno datageen gegevensgeen gegevens

6.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RLAY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Alexis Borisy
Co-Founder & Independent Chairman9.6yrsUS$581.14k0.14%
$ 1.3m
Sanjiv Patel
CEO, President & Director7.7yrsUS$19.77m0.84%
$ 7.7m
Mark Murcko
Co-Founder & Director8.3yrsUS$548.64k0.61%
$ 5.6m
Douglas Ingram
Independent Director5.4yrsUS$548.64k0.015%
$ 140.9k
Linda Hill
Independent Director6.1yrsUS$551.14k0%
$ 0
George Demetri
Member of Oncology Advisory Board4.7yrsgeen gegevensgeen gegevens
Laura Shawver
Independent Director7.7yrsUS$551.14k0.025%
$ 225.4k
Lillian Siu
Member of Oncology Advisory Board4.7yrsgeen gegevensgeen gegevens
Jamilu Rubin
Independent Director5.1yrsUS$558.64k0.041%
$ 378.9k
Pamela Munster
Member of Oncology Advisory Board4.7yrsgeen gegevensgeen gegevens
Trever Bivona
Member of Oncology Advisory Board4.7yrsgeen gegevensgeen gegevens
Dejan Juric
Member of Oncology Advisory Board4.7yrsgeen gegevensgeen gegevens

5.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RLAY wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).